Y-mAbs Therapeutics (NASDAQ:YMAB) Price Target Cut to $18.00 by Analysts at Truist Financial

Y-mAbs Therapeutics (NASDAQ:YMAB) had its price target trimmed by Truist Financial from $21.00 to $18.00 in a report issued on Wednesday,Benzinga reports. The firm currently has a buy rating on the stock.

Several other analysts have also recently issued reports on the stock. Brookline Capital Management assumed coverage on shares of Y-mAbs Therapeutics in a research note on Thursday, December 5th. They issued a “buy” rating and a $17.00 target price on the stock. Oppenheimer began coverage on shares of Y-mAbs Therapeutics in a research note on Monday, November 18th. They issued an “outperform” rating and a $23.00 target price on the stock. HC Wainwright reissued a “buy” rating and issued a $22.00 price target on shares of Y-mAbs Therapeutics in a report on Monday, January 13th. Bank of America decreased their price target on shares of Y-mAbs Therapeutics from $14.00 to $12.00 and set a “neutral” rating on the stock in a report on Wednesday. Finally, Morgan Stanley decreased their price target on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating on the stock in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $19.30.

Y-mAbs Therapeutics Price Performance

NASDAQ YMAB opened at $4.85 on Wednesday. Y-mAbs Therapeutics has a 1 year low of $4.25 and a 1 year high of $18.19. The stock has a market capitalization of $217.23 million, a PE ratio of -8.98 and a beta of 0.65. The company’s 50 day simple moving average is $6.46 and its two-hundred day simple moving average is $10.62.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its earnings results on Tuesday, March 4th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The firm had revenue of $26.50 million during the quarter, compared to analysts’ expectations of $26.70 million. During the same quarter in the prior year, the company earned ($0.02) earnings per share. On average, research analysts anticipate that Y-mAbs Therapeutics will post -0.65 EPS for the current year.

Hedge Funds Weigh In On Y-mAbs Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Infinitum Asset Management LLC bought a new position in shares of Y-mAbs Therapeutics during the 4th quarter valued at $1,218,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Y-mAbs Therapeutics by 17.4% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 52,356 shares of the company’s stock valued at $410,000 after purchasing an additional 7,765 shares during the last quarter. Two Sigma Investments LP grew its holdings in shares of Y-mAbs Therapeutics by 31.6% during the 4th quarter. Two Sigma Investments LP now owns 88,337 shares of the company’s stock valued at $692,000 after purchasing an additional 21,196 shares during the last quarter. Rafferty Asset Management LLC grew its holdings in shares of Y-mAbs Therapeutics by 17.6% during the 4th quarter. Rafferty Asset Management LLC now owns 41,255 shares of the company’s stock valued at $323,000 after purchasing an additional 6,178 shares during the last quarter. Finally, ProShare Advisors LLC bought a new position in shares of Y-mAbs Therapeutics during the 4th quarter valued at $99,000. Institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.